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abstract
 
Sodium balance is maintained by the precise regulation of the activity of the epithelial sodium chan-
nel (ENaC) in the kidney. We have recently reported an extracellular activation of ENaC-mediated sodium trans-
port (I
 
Na
 
) by a GPI-anchored serine protease (mouse channel–activating protein, mCAP1) that was isolated from a
cortical collecting duct cell line derived from mouse kidney. In the present study, we have identified two addi-
tional membrane-bound serine proteases (mCAP2 and mCAP3) that are expressed in the same cell line. We show
that each of these proteases is able to increase I
 
Na
 
 6–10-fold in the 
 
Xenopus
 
 oocyte expression system. I
 
Na
 
 and the
number (N) of channels expressed at the cell surface (measured by binding of a FLAG monoclonal I
 
125
 
-radioiodi-
 
nated antibody) were measured in the same oocyte. Using this assay, we show that mCAP1 increases I
 
Na
 
 10-fold (P 
 

 
0.001) but N remained unchanged (P 
 
 
 
0.9), indicating that mCAP1 regulates ENaC activity by increasing its aver-
age open probability of the whole cell (
 
wc
 
P
 
o
 
). The serum- and glucocorticoid-regulated kinase (Sgk1) involved in
the aldosterone-dependent signaling cascade enhances I
 
Na
 
 by 2.5-fold (P 
 
 
 
0.001) and N by 1.6-fold (P 
 
 
 
0.001),
indicating a dual effect on N and 
 
wc
 
P
 
o
 
. Compared with Sgk1 alone, coexpression of Sgk1 with mCAP1 leads to a
ninefold increase in I
 
Na
 
 (P 
 
 
 
0.001) and 1.3-fold in N (P 
 
 
 
0.02). Similar results were observed for mCAP2 and
mCAP3. The synergism between CAPs and Sgk1 on I
 
Na
 
 was always more than additive, indicating a true potentia-
tion. The synergistic effect of the two activation pathways allows a large dynamic range for ENaC-mediated sodium
regulation crucial for a tight control of sodium homeostasis.
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I N T R O D U C T I O N
 
Sodium balance, extracellular volume, and blood pres-
sure are maintained by the tight control of the activity of
the epithelial sodium channel (ENaC)* (Verrey et al.,
2000). We have recently identified a membrane-bound
serine protease that acts as channel-activating protease,
namely CAP1 (Vallet et al., 1997, 1998; Vuagniaux et al.,
2000). This regulation defines a novel extracellular sig-
naling pathway, which appears to be highly conserved
throughout evolution from 
 
Xenopus
 
 (xCAP1) (Vallet et
al., 1997) to mouse (Vuagniaux et al., 2000), rat (Ada-
chi et al., 2001), and human (Yu et al., 1995). CAP1
activates ENaC through its extracellular serine pro-
tease activity, as evidenced by patch-clamp experiments
(Chraibi et al., 1998). The activation of ENaC by CAP1
can be mimicked by external addition of trypsin, show-
ing that both CAP1 and trypsin act via the same path-
way. Aprotinin, an inhibitor of serine proteases, can
block this effect (Vallet et al., 1997; Vuagniaux et al.,
2000). In epithelial cell lines, like the 
 
Xenopus
 
 kidney
cell line (A6), ENaC appears to be constitutively acti-
vated through the presence of endogenously expressed
serine proteases, since basal transepithelial Na
 

 
 trans-
port cannot be further activated by addition of trypsin
(Vallet et al., 1997). However, the base line Na
 

 
 trans-
port can be inhibited by the addition of aprotinin on
the apical side of the cell and this inhibition can be re-
versed by the addition of trypsin (Vallet et al., 1997). In
 
Xenopus
 
 kidney cells, up to 90% of the amiloride-sensi-
tive electrogenic Na
 

 
 transport can be blocked by apro-
tinin (50 
 

 
M) (Vallet et al., 1997), whereas the mouse
mpkCCD
 
cl4
 
 cell line (derived from the cortical collect-
ing duct; Bens et al., 1999) appears to be only 50% sen-
sitive to aprotinin (Vuagniaux et al., 2000). These find-
ings suggest that ENaC activation is achieved by either a
constitutive, serine protease–independent mechanism
or, alternatively, that the activation depends on more
than one serine protease with different sensitivity to
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aprotinin and that acts in combination within the same
cell. The mechanism by which serine proteases like
CAP1 activates ENaC is not yet understood. CAP1 leads
to a very substantial increase in the open probability of
the Na
 

 
 channel, whereas the number of channels at
the cell surface is either unchanged (Vallet et al., 1997)
or even diminished (Vuagniaux et al., 2000).
The activity of ENaC is tightly controlled by hor-
mones, including aldosterone and vasopressin (for re-
view see Verrey et al., 2000). Components of the al-
dosterone-dependent signaling pathway have been
identified recently. Aldosterone rapidly induced the
expression of Sgk1 kinase (serum- and glucocorticoid-
regulated kinase), a member of the PKB-AKT family of
serine-threonine kinases (Webster et al., 1993). When
coexpressed in 
 
Xenopus laevis
 
 oocytes, Sgk1 stimulates
ENaC activity by 2–3-fold (Chen et al., 1999; Naray-Fejes-
Toth et al., 1999). In 
 
Xenopus
 
 oocytes, Sgk1 increases cell
surface expression of ENaC without changing its open
probability (Alvarez de La Rosa et al., 1999; Loffing et
al., 2001). Recently, it has been demonstrated that the
phosphorylation of Nedd4-2, an ubiquitin protein li-
gase, by Sgk1 may regulate epithelial sodium channel
cell surface expression in the 
 
Xenopus
 
 oocyte system
(Debonneville et al., 2001). It was further demonstrated
that the phosphorylation of Nedd4-2 decreases its affin-
ity for ENaC, thereby diminishing ENaC endocytosis
and/or degradation (Debonneville et al., 2001; Snyder
et al., 2002). These data provided evidence for the miss-
ing link between aldosterone binding to its receptor,
transcription activation of an aldosterone-induced pro-
tein (Sgk1) and the molecular mechanism leading to an
increased cell surface expression of ENaC.
The aims of the present study were twofold: (a) to test
the interaction between two regulatory pathways that can
activate ENaC through extracellular signaling via CAPs
and intracellular signaling via Sgk1, and (b) to identify
further putative membrane-bound serine proteases able
to activate ENaC; in particular, to search for an aprotinin-
resistant protease that could account for the pharmaco-
logical data observed in the mouse CCD cell line.
We demonstrate here the existence of three chan-
nel-activating proteases, namely mouse channel–acti-
vating protease, mCAP1, mCAP2, and mCAP3 within
the same kidney cell. Whereas mCAP2 is inhibited by
aprotinin as well as mCAP1, mCAP3 is not signifi-
cantly inhibited by this serine protease inhibitor. Each
of these membrane-bound serine proteases increases
ENaC-mediated I
 
Na
 
 and potentiates the effect medi-
ated by Sgk1.
 
M A T E R I A L S  A N D  M E T H O D S
 
Identification and Isolation of Full-length Clones
 
Mouse CAP2:
 
Partial mCAP2 sequence was identified by RT-PCR
using degenerated oligonucleotides and total RNA extracted
from mpkCCD
 
cl4
 
 cells as described previously (Vuagniaux et al.,
2000). The primers used were as follows: D1 (sense) 5
 

 
-
AA(AG)TT(CT)CCITGGCA(AG)GT-3
 

 
, nt 
 

 
118 to 
 

 
134; D2
(antisense) 5
 

 
-CC(AG)CA(CT)TC(AG)TCICCCCA-3
 

 
, nt 
 

 
743
to 
 

 
727; D3 (antisense) 5
 

 
-CCIGC(AG)CA(AGT)ATCAT
(AG)TC-3
 

 
, nt 
 

 
629 to 
 

 
613; according to xCAP1 (5
 

 
 and 3
 

 
).
To obtain a full length clone, rapid amplification of 5
 

 
 and 3
 

 
ends (RACE) has been performed (Vuagniaux et al., 2000). For
the 5
 

 
-RACE, successively after mCAP2-specific reverse primers
were used: RC1 (5
 

 
-ACAGGCAAGGATGGAGAGT-3
 

 
, nt position
 

 
812 to 
 

 
794) and adaptor-specific primer dC-5R (5
 

 
-GCAT-
GCTCGAGCGGCCGCAACCCCCCCCCCCCCCCCCC-3
 

 
), and
RC2 (5
 

 
-GATGCTCCCACCACAGAC-3
 

 
, nt position 
 

 
696 to
 

 
679) and the adaptor-specific primer 5R (5
 

 
-GCATGCTC-
GAGCGGCCGCAAC-3
 

 
), according to the manufacturer’s in-
structions (Life Technologies). For 3
 

 
-RACE, reverse transcrip-
tion was performed, using mCAP2-specific primers RC3 (5
 

 
-GAT-
GAGGTGCTTGTCCCAG-3
 

 
, nt position 
 

 
937 to 
 

 
955) and an
oligo(dt) adaptor primer (5
 

 
-CGAGATCTATGCGGCCGCTTTT-
TTTTTTTTTTTTT-3
 

 
). Full-length clone of mCAP2 was ob-
tained by PCR on total RNA extracted from distal colon using S2
(5
 

 
-TAGGAGGATTACCAAAGCAG-3
 

 
, nt position 
 

 
20 to 
 

 
1)
and AS2 (5
 

 
-ATGCCGTAGGTAGGTCTGAA-3
 

 
). 33 cycles were
run consisting of 30 s at 94
 

 
C, 30 s at 54
 

 
C, and 1 min 30 s at
72
 

 
C. After the last cycle, elongation was allowed to proceed for 7
min at 72
 

 
C using Taq polymerase (Roche). PCR products were
purified by gel electrophoresis and, following extraction, cloned
into pT7Blue vector (Novagen) and sequenced
 
. The nucleotide
sequence reported for mCAP2 in this paper has been submitted to
the National Institutes of Health database under EMBL/GenBank/
DDBJ accession no. AY043240.
 
Mouse CAP3:
 
By analyzing a SAGE library (serial analysis of ge-
nome sequences; Robert-Nicoud et al., 2001) and EST database,
a SAGE tag (GATCAAAGAGCACA) corresponding to the re-
cently cloned mouse epithin (AF042822) had been identified
(Kim et al., 1999). Based on sequence information, RT-PCR was
performed on RNA of mpkCCD
 
c14
 
 cells using primers S3 (5
 

 
-
GACCACGCGTCTGAGACC-3
 

 
, nt position 
 

 
38 to 
 

 
20) and
AS3 (5
 

 
-GACAGTTGGAAGCAGCTCTC-3
 

 
, nt position 
 

 
2868 to
 

 
2849). 10 cycles were run, each consisting of 15 s at 94
 

 
C, 30 s
at 58
 

 
C, and 2 min at 68
 

 
C, followed by 20 cycles with continu-
ously increasing elongation times of each 20 s at 68
 

 
C using Taq
polymerase (Expand High Fidelity PCR system; Roche). PCR
product was gel purified, extracted, cloned into pT7Blue vector,
and named mCAP3.
 
Northern Blot Analysis
 
Total RNA was prepared from whole mouse kidney and conflu-
ent mpkCCD
 
c14
 
 cells as described. 20 
 

 
g RNA were run on a
0.8% denaturing glyoxal agarose gel and blotted onto nylon
membranes (Hybond-N; Amersham Biosciences). Membranes
were hybridized with randomly primed 
 
32
 
P-labeled probes for
rENaC (Canessa et al., 1994), mCAP1 (512 bp: nt 
 

 
163 to
 

 
674), mCAP2 (472 bp: nt 
 

 
643 to 
 

 
1115), mCAP3 (603 bp: nt
 

 
2442 to 
 

 
3045).
 
Electrophysiological Experiments in Xenopus Oocytes
 
For functional expression studies, cDNA for mCAP1, mCAP2,
mCAP3, and mouse Sgk1 (provided by O. Staub, Institute of
Pharmacology and Toxicology, Lausanne, Switzerland) were sub-
cloned into pSDS expression vector and in vitro transcribed, as
described previously (Canessa et al., 1994). Purified cRNA were
injected into stage V/VI 
 
Xenopus
 
 oocytes. Routinely, oocytes were
injected with 0.33 ng of each cRNA coding for the rat 
 
	
 
-, 
 


 
- and
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-ENaC subunits in the presence or absence of varying concen-
trations of mCAP1, mCAP2, and mCAP3 and incubated in a
modified Barth (low sodium) solution, as described (Firsov et al.,
1996). Oocytes were incubated overnight in modified Barth sa-
line solution in the presence or absence of 100 
 

 
g/ml aprotinin.
This protocol insures that intracellular sodium is low at the be-
ginning of the measurement and independent of the level of
ENaC expression at the cell surface. Electrophysiological mea-
surements were performed 1–2 d after cRNA injection using the
two-electrode voltage-clamp technique and one bath electrode,
allowing corrections for serial resistance. The oocytes were ex-
posed to 2 
 

 
g/ml trypsin during 2–3 min and amiloride-sensitive
Na
 

 
 current (I
 
Na
 
) was measured in the presence of 120 mM of
Na
 

 
 in frog Ringer’s solution with 5 
 

 
M amiloride at a holding
potential of 
 

 
100 mV.
 
Measurement of N and INa within the Same Oocyte
Cell surface expression has been performed as described (Firsov
et al., 1996). Briefly, 1 ng of tagged rat 	-, 
-, and -ENaC sub-
units was expressed in oocytes either alone or with 4 ng
(mCAP1), 8 ng (mCAP2) or 2 ng (mCAP3) of each CAP and/
or 4 ng Sgk1 cRNA. The density of the channel was then calcu-
lated by binding of iodinated anti-FLAG monoclonal antibody
(M2Ab*) (Sigma-Aldrich). The binding assay was performed at
4C, and INa was measured at room temperature as described. To
deduce the whole cell Po (wcPo), we have used a macroscopic ap-
proach, as described (Firsov et al., 1997) in which the starting
point is the equation, derived from Ohm’s law:
(1)
where (a) INa is the macroscopic amiloride-sensitive current that
measures the total activity of all channels expressed in a cell. (b)
gNa is the single channel conductance measured by patch clamp
in independent experiments. In the presence of sodium it is 5
and 8 pS in the presence of Li (Canessa et al., 1994). (c) (E 
ENa) is assessed by the measurement of membrane potential and
the reversal potential for sodium. For practical purposes, E  ENa
can be set constant by clamping the membrane at 100 mV or
higher, allowing the measurement of changes in Po in function of
the various experimental conditions. (d) N is the total number of
channel molecules (active and inactive) expressed at the cell sur-
face. The binding assay permits to quantitate the total number of
channel molecules at the cell surface, independently of their
function. Having determined with good accuracy INa, gNa, E 
ENa, and N, one can deduce a whole-cell Po (wcPo) that reflects
the activity of all channels expressed in an intact whole cell. The
main advantage of this macroscopic approach is that it takes into
account all channels expressed at the cell surface, whatever their
activity. Our method is therefore distinct from a microscopic ap-
proach that is the classical measurement of Po in membrane
patches (mpPo). This is performed by determining the overall N 
Po of all the active channels and the number of the channels N
present in the patch membrane.
Statistical Analysis
All results are reported as means  SEM. Comparing indepen-
dent sets of data, unpaired t tests were used to determine signifi-
cance. For the measurement of N and INa, a minimum of 3–6
batches of oocytes, 5–10 oocytes per batch, each batch from dif-
ferent animals, were used for each experimental condition. Ex-
periment 1, “ENaC  H2O” vs. “ENaC  mCAP1” vs. “ENaC 
Sgk1” vs. “ENaC  mCAP1  Sgk1”; experiment 2, “ENaC  H2O”
vs. “ENaC  mCAP2” vs. “ENaC  Sgk1” vs. “ENaC  mCAP2 
INa gNa N Po E ENa–( ) ,⋅ ⋅ ⋅=
Sgk1”; experiment 3, “ENaC  H2O” vs. “ENaC  mCAP3” vs.
“ENaC  Sgk1” vs. “ENaC  mCAP3  Sgk1.”
R E S U L T S
Identification of Two Membrane-bound Serine Proteases
in the mpkCCDcl4 Cell Line
mCAP2. By using degenerated oligos to the previously
isolated serine protease from Xenopus xCAP1 and
RACE technique, we identified mCAP2, which en-
codes a 435–amino acid protein. Analysis of the amino
acid sequence and the hydrophobicity plot reveals a
type II–oriented membrane-bound serine protease
with a predicted transmembrane segment (V30–151)
and an extracellular COOH terminus containing a
serine protease catalytic domain with the classical cata-
lytic triad at H243, D288, and S385 and with a poten-
tial proteolytic activation cleavage site at R202V203
(Fig. 1 A). Two cysteines at position C194 and C308
are predicted to connect the prodomain to the main
serine protease domain via a disulfide bond at the ex-
tracellular surface of the cell (Hooper et al., 2001).
The extracellular domain has two potential N-glycosy-
lation sites (N128 and N176) that are used when
mCAP2 is expressed in the Xenopus oocyte system (un-
published data). The catalytic domain is preceded
by a low density lipoprotein receptor class A do-
main (LDLR, F60-V91) and a group A scavenger recep-
tor domain (SRCR, V102-G142) (Fig. 1 A). The ser-
ine protease domain shares homology with mouse
trypsinogen precursor (49%), xCAP1 (45%), mCAP1
(43%), and 80% with a human orthologue hTMPRSS4
(Wallrapp et al., 2000) (Fig. 1 B).
mCAP3. By analysis of the transcriptome of an
mpkCCDcl4 cell line library by SAGE (Robert-Nicoud
et al., 2001) and EST database analysis, we identified a
serine protease we termed mCAP3. mCAP3 is identi-
cal to the recently cloned mouse epithin (Kim et al.,
1999). At the time we started this project, epi-
thin cDNA sequence had not been published. To un-
derline the functional relevance of this serine pro-
tease, we name the third serine protease throughout
our paper mouse channel–activating protein three
(mCAP3). Analysis of the primary sequence revealed
the presence of a transmembrane domain with pre-
dicted type II orientation (Fig. 1 A). COOH terminus
contained the serine protease domain with the cata-
lytic triad (H656, D711, and S805) and a potential ac-
tivation cleavage site at R605V606. The catalytic do-
main was preceded by two complement factor IR-
urchin embryonic growth factor-bone orphogenetic
proteins (CUBs) (C214-F331 and C340-Y444) and
four LDLR (C453-R487, C488-S524, C525-N563 and
C567-L603) domains (Fig. 1 A) (Kim et al., 1999).
mCAP3 shares 47% homology with the mouse trysino-
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gen, 49% with xCAP1, 40% with mCAP2 and 83% with
the human orthologue hMT-SP1 (Takeuchi et al.,
1999) (or Matriptase; Lin et al., 1999) (Fig. 1 B).
Primary sequence comparison of the catalytic do-
main of mCAP1, mCAP2, mCAP3, and trypsin re-
vealed the presence of an aspartate (mCAP1, D232;
mCAP2, D379; mCAP3, D799) at the S1 site (Schech-
ter and Berger, 1967) and 2 glycines at the entry of
the S1 pocket (mCAP1, G259 and G269; mCAP2,
G405 and G415; and mCAP3, G827 and G837) which
direct the specificity of serine proteases (Perona and
Craik, 1995, 1997) (Fig. 1 C). This suggests that all
three serine proteases are specific for the positively
charged P1 amino acids. The presence of a proline
residue (mCAP1, P268; mCAP2, P414; and mCAP3,
P836) instead of a tyrosine residue at the Na-induced
allosteric regulation of catalytic activity site in serine
proteases suggests that the catalytic activity of three
serine proteases is not sensitive to extracellular Na
concentration variations (Dang and Di Cera, 1996)
(Fig. 1 C).
Northern blot analysis showed that mCAP1, mCAP2,
mCAP3, and 	ENaC subunit are expressed, as ex-
pected, in mpkCCDc14 cell line. Whereas mCAP3 ex-
pression was expressed in the cell line and the kidney
at a level similar to that of mCAP1, mCAP2 expression
was low and not detectable in the whole kidney (Fig.
2). The three membrane-bound proteases and the
	ENaC subunit were also expressed in epithelia
known to express an amiloride-sensitive sodium trans-
port (lung and colon). A similar pattern of expression
was also found in small intestine and stomach. In these
tissues, the role of ENaC and/or CAPs remains to be
established.
Figure 1. mCAP1, 2, and 3 are membrane-bound serine pro-
teases. (A) Structural properties of the three mCAPs (mCAP1,
mCAP2, and mCAP3). The amino acid sequence of each protein
was scanned using ProfileScan algorithm to confirm the presence
of domains indicated. Numbers delineate the location of each do-
main. (B) A representative phylogenetic tree of the GPI-anchored
mCAP1 and type II transmembrane mCAP2 and mCAP3 serine
protease family proteins. Multiple alignment was generated by the
clustal W program (mCAP1, AAG1705; hProstasin, Q16651;
xCAP1, AAB969054; mCAP2, AY043240; hTMPRSS4-1, CAC60389;
hTMPRSS4–2; MT-SP2, Q9NRS4; mTMPRSS2; epitheliasin,
AAF97867; hTMPRSS2, AAC51784; mTMPRSS3, CAC83350;
hTMPRSS3, P57727; mCAP3; epithin, AAD02230; hMT-SP1,
AAF00109; xMT-SP1, BAB08218). (C) Amino acid alignment of
the serine protease catalytic domain of mCAP1, mCAP2, and
mCAP3 with mouse trypsinogen precursor (1–246), was per-
formed using Pileup program (Genetic Computer Group). Gray
and black boxes indicate similar and identical residues, respec-
tively. The catalytic triad (H, D, and S, asterisks), the amino acids
implicated in the P1 substrate specificity (closed circle), and the
position for Na sensibility (open circle) are indicated.
Figure 2. Coexpression of all three serine proteases with ENaC.
Multiple tissue Northern blot containing 20 g of RNA/lane were
hybridized with cDNA fragments of the rat 	ENaC, mouse CAP1,
CAP2, CAP3, and GAPDH genes, as described in materials and
methods. mRNA transcript lengths are indicated.
195 Vuagniaux et al.
ENaC Activation by mCAP1, mCAP2,
and mCAP3 in Xenopus Oocytes
In the Xenopus oocytes, ENaC activity is recorded as an
amiloride-sensitive Na current (INa). As shown in Fig. 3 A
(lanes 1–4), mCAP1 increased ENaC activity 5–10-fold. In-
creasing amounts of cRNA coding for mCAP1 were tested
and a maximal effect was observed with 4 ng mCAP1.
mCAP2 and mCAP3 (Fig. 3, lanes 5–8 and 9–12) were
also able to increase ENaC activity by 4–8-fold, the maxi-
mal effect for mCAP2 was observed with 8 ng of injected
cRNA and for mCAP3 with only 2 ng cRNA. At higher
concentrations of mCAP3 (4–12 ng), ENaC activation was
inhibited, (P  0.01) presumably by competition for the
translational machinery. Consequently, in all further ex-
periments we used 4 ng (mCAP1), 8 ng (mCAP2), and 2
ng (mCAP3) that induce maximal activation of ENaC.
Trypsin can activate the INa (Fig. 3 B, lane 2 vs. 1).
The activity of ENaC can be partially blocked by incu-
bating the oocytes in the presence of the serine pro-
tease inhibitor aprotinin (lane 3), suggesting that
ENaC has been weakly activated by endogenous serine
proteases. This block can be overcome by further addi-
tion of trypsin in the medium (lane 4). Activation of
ENaC in the presence of mCAP1 (lane 5) cannot be
further increased by trypsin (lane 6), whereas preincu-
bation in the presence of aprotinin inhibits ENaC activ-
ity to base line level (lane 7), which can then be re-
stored by trypsin (lane 8). In the same assay, one can
observe that mCAP2 similarly activates ENaC (lanes
9–12). mCAP3 was also able to fully activate ENaC (lane
13), to a level that was not further increased by trypsin
(lane 14). Unlike mCAP1 or mCAP2, this effect was
aprotinin resistant (lane 15) and could not be further
increased by perfusion of trypsin (lane 16). These data
indicate that the mCAP3 aprotinin binding site, unlike
that of mCAP1 and mCAP2, has a low affinity for the in-
hibitor. mCAP3 is therefore a good candidate for being
a serine protease responsible for the aprotinin-resistant
component observed in mpkCCDc14 cells.
Functional Interaction between CAPs and Sgk1
in the Xenopus Oocyte System
To test whether mouse CAPs and Sgk1 interact func-
tionally, oocytes injected with rENaC FLAG-tagged sub-
units (rENaCf) were coexpressed either individually or
with each protease (mCAP), or with Sgk1 or both to-
gether. If the two activation pathways are fully indepen-
dent of each other but have a final common effector
(ENaC), a true potentiation should be observed, i.e.,
any synergistic effect should be more than additive. In
Table I (mCAP1-Skg1), Table II (mCAP2-Sgk1), Table
III (mCAP3  Sgk1), the data are presented in abso-
lute values, allowing to quantify the synergism ob-
served.
mCAP1 and Sgk1
When rENaCf was coexpressed with mCAP1 (Table I),
N did not change (P  0.9) (column a) whereas INa
(column b) increased 11-fold (P  0.001) compared
with rENaCf expressed alone. When rENaCf was coex-
pressed with Sgk1, we observed a 1.6-fold in N (P 
0.01) and a 2.6-fold increase in INa (P  0.001). When
Sgk1 and mCAP1 were coexpressed, INa increased 9.1-
fold (P  0.001) and N by only 0.3-fold (P  0.05)
when compared with oocytes injected with Sgk1 alone.
If the effect of the two pathways was just additive, their
combined effect would not exceed the sum of the two
cRNA given alone. For INa it should not exceed 13 A
per oocyte, but we do observe 24 A/oocyte. Thus, the
data indicate a strong and highly significant (P 
0.001) potentiation between mCAP1 and Sgk1 for the
Figure 3. Functional analysis of mCAP1–3 in Xenopus oocytes.
(A) Comparison of the effect of mCAP1, mCAP2, and mCAP3 on
INa in Xenopus oocytes. Oocytes were injected with rat ENaC sub-
units in the presence of either water (open bar, lane 1) or increas-
ing amounts (2, 4, and 8 or 12 ng) of mCAP1 (closed bar, lanes
2–4), mCAP2 (light gray bar, lanes 5–8), or mCAP3 (dark gray bars,
lanes 9–12). §§, P  0.01 versus conditions with other amounts of
the same cRNA protease. n  12 measured oocytes. (B) Effect of
preincubation with aprotinin (lanes 3, 4, 7, 8, 11, 12, 15, 16) or
perfusion of trypsin (gray bars, lanes 2, 4, 6, 8, 10, 12, 14, 16) on
oocytes injected with either rENaC and water (lane 1–4) or rENaC
together with 4 ng mCAP1 (lane 5–8), 8 ng mCAP2 (lane 9–12),
and 2 ng mCAP3 (lane 13–16). n  12 measured oocytes.
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INa effect, whereas the synergism for the N effect was
small (though significant) and less than additive. To
verify that mCAP1 was expressed for its maximal effect,
we tested the effect of external trypsin. As shown in Ta-
ble I, trypsin (column d) was able to increase baseline
INa only in ENaC or ENaC  Sgk1–injected oocytes. By
contrast, trypsin did not elicit any further increase in
INa when mCAP1 was expressed. These data indicate
that mCAP1 has already fully activated ENaC expressed
at the surface of the oocyte. INa/N (column c) is a pa-
rameter from which one can deduce the average open
probability in a whole cell wcPo (see materials and
methods and discussion). As shown in Table I,
mCAP1 increased INa/N by 13-fold (P  0.001), Sgk1
alone had a minimal effect (1.5-fold; P  0.05), mCAP1
and Sgk1 lead to an 11-fold increase in INa/N (P 
0.001), not significantly different from stimulation ob-
served with CAP1 alone. Upon activation by trypsin
(column e), INa/N increased 5.9-fold in controls (P 
0.001) and 4.7-fold in Sgk1 injected oocytes (P 
0.001). No further significant increase in INa/N was ob-
served in mCAP1 or mCAP1  Sgk1–coinjected oo-
cytes.
mCAP2 and Sgk1
When rENaCf was coexpressed with mCAP2 (Table II),
N did not change (P  0.6) (column a), whereas INa
(column b) increased 8.4-fold (P  0.001) compared
with rENaCf expressed alone. When rENaCf was coex-
pressed with Sgk1, we observed a 1.6-fold increase in N
(P  0.01) and a 2.4-fold increase in INa (P  0.001).
When Sgk1 and CAP2 were coexpressed, INa increased
7.6-fold (P  0.001) and N by 1.4-fold (P  0.06) when
compared with oocytes injected with Sgk1 alone. If the
effect of the two pathways was just additive, their com-
bined effect would not exceed the sum of the two
cRNA given alone. For INa it should not exceed 5.4 A/
oocyte, but we do observe 9.1 A/oocyte. Thus, the
data indicate a strong and highly significant (P 
0.001) potentiation between mCAP2 and Sgk1 for the
INa effect, whereas the synergism for the N effect did
not reach the level of significance (P  0.06) and was
less than additive. To verify that mCAP2 was expressed
maximally, we tested the effect of external trypsin. As
shown in Table II, trypsin (column d) was able to in-
crease baseline INa only in ENaC or ENaC  Sgk1–
injected oocytes. By contrast, trypsin did not elicit any
further increase in INa when mCAP2 was expressed.
These data indicate that mCAP2 has already fully acti-
vated ENaC expressed at the surface of the oocyte. As
shown in Table II (column d), mCAP2 increased INa/N
by ninefold (P  0.001), Sgk1 alone had a small effect
(2.4-fold; P  0.05), and mCAP2 and Sgk1 led to a 10-
fold increase in INa/N (P  0.001), not significantly dif-
ferent from the stimulation observed with mCAP2
alone (P  0.76). Upon activation by trypsin (column
e), INa/N increased 7.3-fold in controls (P  0.001) and
4.4-fold in Sgk1-injected oocytes (P  0.001). No fur-
ther significant increase in INa/N was observed in
mCAP2 or mCAP2  Sgk1–coinjected oocytes.
mCAP3 and Sgk1
When rENaCf was coexpressed with mCAP3 (Table III),
N did not change (P  0.7) (column a), whereas INa
(column b) increased 6.8-fold (P  0.001) compared
with rENaCf expressed alone. When rENaCf was coex-
pressed with Sgk1, we observed a 1.8-fold increase in N
(P  0.001) and a 3.6-fold increase in INa (P  0.001).
T A B L E  I
Effect of Sgk1 and CAP1 on ENaC-mediated Sodium Current (INa) and Cell Surface Expression (N)
Measured by Monoclonal Antibody Binding to Flagged 	
ENaC
Before trypsin treatment After trypsin treatment
cRNA injection n (oocyte) N (f mole/oocyte) INa INa/N INa INa/N INa/N  tryp/INa/N  tryp
a b c d e e/c
A/oocyte A/f mole A/oocyte A/f mole
ENaC  H2O 40 0.085  0.007 1.1  0.2 14.2  1.0 6.2  1.0 84.1  12.3 5.9 (P  0.01)
ENaC  mCAP1 35 0.085  0.010 11.9  1.5 182.6  24.3 11.4  1.5 175.9  23.3 1.0 (ns)
ENaC  Sgk1 31 0.139  0.014 2.7  0.4 21.7  2.9 12.0  1.6 102.9  14.2 4.7 (P  0.01)
ENaC  Sgk1  mCAP1 26 0.186  0.015 24.5  1.8 162.8  21.2 24.4  1.7 149.3  14.1 0.9 (ns)
INa and N were measured in the same oocyte as described in materials and methods. 26–40 oocytes from a minimum of 5 different batches were measured
for each experimental condition.
t test results for N: control vs. CAP1, P  0.9; control vs. Sgk1, P  0.001; control vs. Sgk1  mCAP1, P  0.001; mCAP1 vs. Sgk1, P  0.001; mCAP1 vs.
Sgk1  mCAP1, P  0.001; Sgk1 vs. Sgk1  mCAP1, P  0.02.
t test results for INa: control vs. CAP1, P  0.001; control vs. Sgk1, P  0.001; control vs. Sgk1  mCAP1, P  0.001; mCAP1 vs. Sgk1, P  0.001; mCAP1 vs.
Sgk1  mCAP1, P  0.001; Sgk1 vs. Sgk1  mCAP1, P  0.001.
t test results for INa/N: control vs. CAP1, P  0.001; control vs. Sgk1, P  0.03; control vs. Sgk1  mCAP1, P  0.001; mCAP1 vs. Sgk1, P  0.001; mCAP1
vs. Sgk1  mCAP1, P  0.55; Sgk1 vs. Sgk1  mCAP1, P  0.001.
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When Sgk1 and mCAP3 were coexpressed, INa increased
7.3-fold (P  0.001) and N by only 0.14-fold (P  0.4)
compared with oocytes injected with Sgk1 alone. If the
effect of the two pathways was just additive, their com-
bined effect would not exceed the sum of the two cRNAs
given alone. For INa, it should not exceed 5.2 A/
oocyte, but we do observe 13.2 A/oocyte. Thus, the
data indicate a strong and highly significant (P  0.001)
potentiation between mCAP3 and Sgk1 for the INa ef-
fect, whereas the synergism for the N effect was signifi-
cant but small and less than additive. To verify that
mCAP3 was expressed maximally, we tested the effect of
external trypsin. As shown in Table III, trypsin (column
d) was able to increase baseline INa only in ENaC or
ENaC  Sgk1–injected oocytes. By contrast, trypsin did
not elicit any further increase in INa when mCAP3 was
expressed alone or with Sgk1. These data indicate
mCAP3 has already fully activated ENaC expressed at
the surface of the oocyte. As shown in Table III, mCAP3
increased INa/N by 9.4-fold (P  0.001), Sgk1 alone had
a small effect (twofold (P  0.01), and mCAP3 and Sgk1
led to 7.6-fold increase in INa/N (P  0.001), not signifi-
cantly different from stimulation observed with CAP3
alone (P  0.14). Upon activation by trypsin (column
e), INa/N increased 6.7-fold in controls (P  0.001) and
5.3-fold in Sgk1-injected oocytes (P  0.001). No fur-
ther significant increase in INa/N was observed in
mCAP3 or mCAP3  Sgk1–coinjected oocytes.
In summary, qualitatively, the effects of mCAP1,
mCAP2, or mCAP3 are remarkably similar. Since base-
T A B L E  I I
Effect of Sgk1 and CAP2 on ENaC-mediated Sodium Current (INa) and Cell Surface Expression (N) 
Measured by Monoclonal Antibody Binding to Flagged 	
ENaC
Before trypsin treatment After trypsin treatment
cRNA injection n (oocyte) N (f mole/oocyte) INa INa/N INa INa/N INa/N  tryp/INa/N  tryp
a b c d e e/c
A/oocyte A/f mole A/oocyte A/f mole
ENaC  H2O 32 0.065  0.008 0.5  0.1 10.1  1.5 3.9  0.9 73.3  13.8 7.3 (P  0.01)
ENaC  mCAP2 28 0.070  0.007 4.2  0.9 90.0  23.0 4.9  0.9 94.2  20.0 1.0 (ns)
ENaC  Sgk1 26 0.105  0.016 1.2  0.1 24.1  7.2 6.4  0.7 106.2  18.9 4.4 (P  0.01)
ENaC  Sgk1  mCAP2 19 0.151  0.018 9.1  1.3 80.7  14.8 12.4  1.1 108.4  16.3 1.3 (ns)
INa and N were measured in the same oocyte as described in materials and methods. 19–32 oocytes from a minimum of 5 different batches were measured
for each experimental condition.
t test results for N: control vs. CAP2, P  0.6; control vs. Sgk1, P  0.02; control vs. Sgk1  mCAP2, P  0.001; mCAP2 vs. Sgk1, P  0.04; mCAP2 vs. Sgk1 
mCAP2, P  0.001; Sgk1 vs. Sgk1  mCAP2, P  0.06.
t test results for INa: control vs. CAP2, P  0.001; control vs. Sgk1, P  0.001; control vs. Sgk1  mCAP2, P  0.001; mCAP2 vs. Sgk1, P  0.001; mCAP2 vs.
Sgk1  mCAP2, P  0.003; Sgk1 vs. Sgk1  mCAP2, P  0.001.
t test results for INa/N: control vs. CAP2, P  0.001; control vs. Sgk1, P  0.04; control vs. Sgk1  mCAP2, P  0.001; mCAP2 vs. Sgk1, P  0.01; mCAP2
vs. Sgk1  mCAP2, P  0.8; Sgk1 vs. Sgk1  mCAP2, P  0.001.
T A B L E  I I I
Effect of Sgk1 and CAP3 on ENaC-mediated Sodium Current (INa) and Cell Surface Expression (N) 
Measured by Monoclonal Antibody Binding to Flagged 	
ENaC
Before trypsin treatment After trypsin treatment
cRNA injection n (oocyte) N (f mole/oocyte) INa INa/N INa INa/N INa/N  tryp/INa/N  tryp
a b c d e e/c
A/oocyte A/f mole A/oocyte A/f mole
ENaC  H2O 34 0.067  0.008 0.5  0.1 9.3  1.4 2.9  0.5 62.8  12.1 6.7 (P  0.01)
ENaC  mCAP3 15 0.061  0.013 3.4  0.5 87.6  20.1 4.4  0.6 101.9  17.5 1.2 (ns)
ENaC  Sgk1 28 0.122  0.015 1.8  0.3 18.6  2.7 8.7  1.1 99.2  15.4 5.3 (P  0.01)
ENaC  Sgk1  mCAP3 30 0.140  0.014 13.2  1.1 141.3  20.7 15.7  1.5 150.8  18.4 1.1 (ns)
INa and N were measured in the same oocyte as described in materials and methods. 15–34 oocytes from a minimum of 5 different batches were measured
for each experimental condition.
t test results for N: control vs. CAP3, P  0.7; control vs. Sgk1, P  0.001; control vs. Sgk1  mCAP3, P  0.001; mCAP3 vs. Sgk1, P  0.01; mCAP3 vs. Sgk1 
mCAP3, P  0.001; Sgk1 vs. Sgk1  mCAP3, P  0.4.
t test results for INa: control vs. CAP3, P  0.001; control vs. Sgk1, P  0.001; control vs. Sgk1  mCAP3, P  0.001; mCAP3 vs. Sgk1, P  0.003; mCAP3 vs.
Sgk1  mCAP3, P  0.001; Sgk1 vs. Sgk1  mCAP3, P  0.001.
t test results for INa/N: control vs. CAP3, P  0.001; control vs. Sgk1, P  0.002; control vs. Sgk1  mCAP3, P  0.001; mCAP3 vs. Sgk1, P  0.001; mCAP3
vs. Sgk1  mCAP3, P  0.1; Sgk1 vs. Sgk1  mCAP3, P  0.001.
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line INa varies by a factor of two from experiment to ex-
periment (see column b, ENaC-injected oocytes of
each table), comparisons between CAPs are also shown
in Fig. 4 and summarized as relative changes normal-
ized to ENaC and/or water-injected oocytes. It is evi-
dent that, when corrected for the different baseline val-
ues, the effects of each CAP are also quantitatively very
similar.
D I S C U S S I O N
Membrane-bound Serine Proteases: a Novel Signaling
Cascade in Epithelial Cells?
In this study, we describe the identification of three dis-
tinct mammalian membrane-bound serine proteases
that are present in the same cell type. mCAP1 is a GPI-
anchored protein, whereas mCAP2 and mCAP3 belong
to the type 2 transmembrane serine proteases (TTSPs)
family (Hooper et al., 2001). A few members of mem-
brane-bound serine proteases have been so far bio-
chemically characterized or their cell surface localiza-
tion has been demonstrated (Hooper et al., 2001).
Based on a conserved disulfide bond linking the pro-
and the catalytic domains, one can predict that TTSPs
are active in their membrane-bound form. Interest-
ingly, some TTSPs have a high degree of autocatalytic
activity and the targeting of the TTSPs to the apical
membrane of an epithelial cell involves its proteolytic
domain (Zheng et al., 1999; Hooper et al., 2001). Re-
cently, a recombinant Kunitz-type serine protease in-
hibitor, which is similar to aprotinin, was tested in
human bronchial epithelial cells and shown to effi-
ciently block ENaC-mediated Na transport in the lung
(Bridges et al., 2001). Homology screening of a human
airway epithelial cDNA library identified human prosta-
sin (the orthologue of mCAP1) and TMPRSS2, a ho-
mologue of mCAP2 or the human TMPRSS4 (Donald-
son et al., 2002). These authors demonstrated that
prostasin increased ENaC activity, whereas TMPRSS2
had a strong antagonist effect in the Xenopus oocyte sys-
tem. In our screen, we were not able to identify epithe-
liasin, the mouse homologue of TMPRSS2, in the
mpkCCDc14 cell line. In our study, mCAP2 clearly has
an agonist effect on ENaC activation, which is very simi-
lar to that of mCAP1 or prostasin. It is not clear, at
present time, what the structural difference is between
the two proteases that might explain this striking func-
tional difference. Our present working hypothesis is
that mCAP1–3 are coexpressed at the apical membrane
of, for example, kidney cells, and exert their effect ei-
ther together on channel activation or by a catalytic cas-
cade similar to the serine protease cascade of the blood
clotting system. For xCAP1, we have reported recently
the importance of the GPI anchor for the activation of
ENaC at the plasma membrane (Vallet et al., 2002), but
the role of the transmembrane domains of mCAP2 or
mCAP3 in ENaC activation has not yet been studied.
How and in which sequence each of the serine pro-
teases may activate ENaC is not known.
Control of Cell Surface Expression of ENaC and its Open 
Probability by Two Distinct and Synergistic-signaling 
Pathways Extends the Dynamic Range of Channel Regulation
The Xenopus oocyte expression system allows to quan-
tify cell surface expression of epithelial sodium chan-
nels and to determine the channel open probability in
a whole cell (wcPo) (Firsov et al., 1996, 1997) (see ma-
terials and methods). According to the single chan-
nel measurement after trypsin activation reported by
Chraibi et al. (1998), one can make the assumption
that gNa remains unchanged under our experimental
conditions. Under a voltage clamp set constant at 100
mV, one can now get a fairly good estimate of the wcPo
and how it is affected by our experimental maneuvers.
Under low sodium incubation, we reported a INa/N of
4.82 mA/fmole (Firsov et al., 1996). We can calculate a
Figure 4. Synergistic activation of mCAP1–3 and Sgk1 on ENaC
activity. (A) Oocytes were injected with cRNA coding either for 	,

, and FLAG-tagged rENaC subunits (rENaCf) and water (lane
1) or rENaCf together with mCAP1 (lane 2), mCAP2 (lane 3),
mCAP3 (lane 4), Sgk1 (lanes 5–8), or both Sgk1 and mCAP1 (lane
6), Sgk1 and mCAP2 (lane 7), and Sgk1 and mCAP3 (lane 8). INa
was measured in absence (open bar) and after perfusion of trypsin
(closed bar) and normalized to INa in oocytes injected with rENaC
alone. n  15 measured oocytes per experimental condition taken
from Tables I–III. (B) Normalized oocyte cell surface expression
of rENaCf in oocytes experiments described in A. Water, lane 1;
mCAP1, lane 2; mCAP2, lane 3; mCAP3, lane 4; Sgk1, lane 5;
mCAP1  Sgk1, lane 6; mCAP2  Sgk1, lane 7; mCAP3  Sgk1,
lane 8. ***, P  0.001 versus rENaCf  water.
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wcPo of around 0.018, assuming a heterotetrameric
channel (Firsov et al., 1998). In the present study, we
injected three times less ENaC cRNA, leading to a
lower cell surface expression of ENaC (N varies from
0.06–0.08 fmole/oocyte [present study] vs. 0.5 fmole/
oocyte [Firsov et al., 1998]) but with a relatively high
current (INa, 0.5–1 A/oocyte with a INa/N varying be-
tween 9 and 14 A/fmole (See Table I–III). From these
data, one can calculate a wcPo of 0.05. For ENaC, the es-
timation of Po in membrane patches (mpPo) has been
reported to be extremely variable (Palmer and Frindt,
1988; Palmer and Frindt, 1996). In native membranes
from salt-repleted rat, no channel activity was detect-
able. It is likely that this observation is due to the lack
of sensitivity of the patch method to detect channels
with very low Po or very few channels with higher Po. In
native membrane from salt-depleted animals with high
plasma aldosterone levels, mpPo ranged from 0.05 to
0.9 with an average value of 0.5 (Pacha et al., 1993).
Due to the wide distribution of spontaneous Po and
the slow transitions between open and closed states, the
quantitation of the number of active channels in the
membrane patch is difficult, leading to overestimation
of Po. This overestimation could be experimentally doc-
umented by direct comparisons of the two methods for
a mutant channel of the 
 subunit (G37S) leading to a
50% decrease in Po (Firsov et al., 1997). The alterna-
tive wcPo method used in the present study is therefore
a useful quantitative approach to assess the effect of
CAP or Sgk1 on Po in an intact cell.
mCAP1, mCAP2, and mCAP3 Increase wcPo 
without Changing N
Upon CAP stimulation, it is evident that the wcPo of
ENaC can reach very high values (up to 0.65 for
mCAP1), which cannot be further increased by exter-
nal trypsin. None of the three CAPs tested changed the
cell surface expression of ENaC. It would appear that
this signaling pathway is unique in controlling the gat-
ing of the channel from an external site, which is
trypsin sensitive (Chraibi et al., 1998). The molecular
mechanisms remain elusive. It has been suggested that
the  subunit was a substrate for CAP (Masilamani et
al., 1999) but, so far, no biochemical experimental evi-
dence has supported this hypothesis. A second impor-
tant issue is to know whether CAPs are regulated by
hormones or other factors. In our experimental sys-
tems, we have not been able to demonstrate any effect
of aldosterone on the mRNA abundance of either of
the three CAPs expressed in mpkCCD cells (unpub-
lished data). It is, however, interesting to note a recent
article reporting that aldosterone increased in vitro the
expression of mCAP1/prostasin mRNA and protein in
a kidney cell line (M1) and in vivo in adrenalectomized
rats (Narikiyo et al., 2002).
Dual Effect of Sgk1 on N and wcPo
Our data clearly indicate that Sgk1 increases N signifi-
cantly in three large and independent series of experi-
ments (Table I–III and Fig. 4), confirming previous re-
ports showing an over twofold increased expression of
	
-FLAG ENaC measured by 125I-protein G binding to
the anti-FLAG monoclonal antibody (Alvarez de La
Rosa et al., 1999), with no evidence of an effect on Po
measured in membrane patches. More recently, it has
been shown that Sgk1 induced a proportional increase
in INa and in N (about threefold) in the Xenopus oocyte
system, suggesting that the effect is entirely mediated
by a change in ENaC cell-surface expression (Loffing et
al., 2001) that may occur in vivo only in a restricted part
of the aldosterone-sensitive distal nephron (proximal
ASDN). Our data differ somewhat from these two stud-
ies in the sense that we do observe a small but highly
significant and highly reproducible effect of Sgk1 on
INa/N (1.52, P  0.001, Table I; 2.4, P  0.001 Table II;
and 2.0, P  0.001) that is consistently higher than that
observed on N (Table III), suggesting that Sgk1 has an
additional effect on wcPo. The reasons for that differ-
Figure 5. Model of CAPs and Sgk1 action on ENaC. (A) CAPs
increase the open probability of ENaC channels. The substrate of
CAPs may be ENaC or protein(s) associated with ENaC. (B) Model
of Sgk1 action on ENaC. Sgk1 principally increases the number of
active channels at the cell surface by diminishing the removal of
the channels from the cell surface and by increasing its Po. (C)
CAPs proteases and Sgk1 act synergically on the channel open
probability and cell surface expression.
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ence are not clear, but our experimental protocol dif-
fers significantly from those of the two previous studies
in the sense that we have measured INa and N in the
same individual oocyte, allowing a better quantitation
of any effect on N and/or Po. On the other hand, val-
ues of mpPo reported in one study were 0.83 for ENaC-
injected oocytes and 0.87 for ENaC  Sgk1–injected
oocytes (Alvarez de La Rosa et al., 1999). As discussed
above, such high baseline values may not reflect the
physiological regulation of ENaC in a kidney cell and the
technique may underestimate the number of silent or
weakly active channels in the membrane. Interestingly,
we reported previously that the Liddle mutation has
also a dual effect on N and Po (Firsov et al., 1996), very
similar to the effect of Sgk1 reported here. Since Sgk1
is proposed to mediate its effects on ENaC through the
phosphorylation of Nedd4–2 (Debonneville et al.,
2001), which binds to the PPXY motif of ENaC, which is
precisely the consensus for the Liddle mutation, it would
make sense that the Sgk1-Nedd4-2-ENaC–signaling cas-
cade involves a dual mechanism of ENaC activation.
CAP and Sgk1: Synergism of Potentiation
This paper demonstrates a synergism between the two
signaling pathways in the oocyte expression system
(Figs. 4 and 5). mCAP1, mCAP2, or mCAP3 have no ef-
fect on cell surface expression of ENaC, but increase
wcPo by 7–10-fold. On the other hand, Sgk1 increases
the number of channels expressed at the cell surface by
twofold, without changing wcPo. When the two signal-
ing pathways are activated together, a 20–30-fold in-
crease is observed. The synergism is therefore more
than additive and is a true potentiation. The possible
mechanisms for this synergism has not yet been stud-
ied. It will be interesting to examine whether mCAPs
can bind directly to ENaC by protein–protein interac-
tion through their extracellular (mCAP1, mCAP2, or
mCAP3) and/or through their cytoplasmic domains
(mCAP2 or mCAP3). Another possible mechanism
would imply a protein–protein interaction between
Sgk1 and the intracellular COOH termini of mCAP2 or
mCAP3 as a potential target for phosphorylation. It re-
mains to demonstrate that the synergism we describe
here operates in vivo in the principal cell of CCD in re-
sponse to aldosterone. Gene inactivation of Sgk1
(Wulff et al., 2001) and mCAP1 (Rubera et al., 2002),
mCAP2, and mCAP3 will help to dissect the respective
role of the two signaling pathways. Despite large varia-
tions in salt intake, the kidney is able to maintain so-
dium balance and the extracellular volume within nar-
row margins, an important factor in the control of
blood pressure. The ASDN plays a key role in adjusting
sodium reabsorption to diet intake that may vary from
1 g NaCl/d to 40 g/d. The fine control of ENaC
through the control of its cell surface expression and
its open probability by aldosterone acting, on one
hand, on an intracellular signaling cascade and, on the
other hand, on a serine protease that controls gating
from the extracellular compartment, should provide
the large range required for rapid and long term regu-
lation of sodium transport in ASDN.
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